March 1, 2024
MSD said on February 29 that it has filed for a label expansion of its PD-1 inhibitor Keytruda (pembrolizumab) for the drug’s use in combination with concurrent chemoradiotherapy (CCRT) for the treatment of locally advanced cervical cancer in Japan. Keytruda...read more